28.80 USD
▲-0.57+4.27%
盘后 27.62 0.00%
2026-08-03
市值
$3.62B
市盈率
—
EPS
-3.23
股息率
—
52 周区间
8.88 – 31.74
成交量
845.21K
Beta
0.80
目标价
36.83
52W 低 8.8852W 高 31.74
价格走势
公司简介
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in...